Symptomatic and hemodynamic benefit of pentaerythrityl tetranitrate and hydralazine in a case of congestive heart failure

Clin Res Cardiol. 2009 Oct;98(10):677-9. doi: 10.1007/s00392-009-0053-x. Epub 2009 Jul 31.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Cardiomyopathy, Dilated / complications
  • Cardiomyopathy, Dilated / drug therapy*
  • Cardiomyopathy, Dilated / physiopathology
  • Drug Therapy, Combination
  • Dyspnea / drug therapy
  • Dyspnea / etiology
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Heart Failure / physiopathology
  • Hemodynamics / drug effects*
  • Humans
  • Hydralazine / therapeutic use*
  • Male
  • Pentaerythritol Tetranitrate / therapeutic use*
  • Recovery of Function
  • Treatment Outcome
  • Vasodilator Agents / therapeutic use*
  • Ventricular Function, Left / drug effects*

Substances

  • Vasodilator Agents
  • Pentaerythritol Tetranitrate
  • Hydralazine